IndustryCompany release

MacroGenics reports $288M cash and 2028 runway, putting B7-H3 ADC MGC026 in head and neck cancer first

🇺🇸 Macrogenics Inc (MGNX) · Fri 13 Nov 2026

The US biotech says non-dilutive deals, including a manufacturing sale and a ZYNYZ royalty sale, extend its funding as it focuses on investigational ADC MGC026.

MacroGenics published a corporate presentation on 12 November 2026 reporting $288M in cash and marketable securities as of 30 September 2026. The company guides to a cash runway through 2028.

The presentation highlights $359M of non-dilutive capital raised across 2025 and 2026. Two of the sources named are the sale of the company's manufacturing operations and a sale of its royalty on ZYNYZ.

Pipeline priorities centre on MGC026, an investigational antibody-drug conjugate (ADC) directed at B7-H3. Squamous cell carcinoma of the head and neck is the lead indication for the programme.

MacroGenics also lists other candidates in its portfolio, including further ADCs, T-cell engagers and dual checkpoint molecules. The source material available to VigiEye did not include trial data, regulatory timelines or detailed development plans for these assets.

What it means for your team

  • Market-access and HTA teams tracking head and neck cancer should note MGC026 is investigational; no approval or filing is described in the material reviewed.
  • The sale of MacroGenics' manufacturing operations may be relevant to quality and supply-chain teams assessing partners, though the source summary gives no detail on transition arrangements.
  • The runway guidance through 2028 indicates the company expects to fund its priority programmes for roughly the next two years.

Company's press release (SEC filing): Macrogenics Inc ↗

Article written by VigiEye from the official source (Macrogenics Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →